Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Tobramycin clearance in a cystic fibrosis patient on haemodialysis: implications for dosing

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: BROWN, Catherine (Alfred Health, Pharmacy)
  • Co-author(s): Catherine Elizabeth Brown: Pharmacy, Alfred Health, Melbourne, Australia
    Vanessa Inserra: Pharmacy, Alfred Health, Melbourne, Australia
    Scott Wilson: Renal Medicine, Alfred Health, Melbourne, Australia
  • Abstract:

    Background

    In the era of conventional high-flux haemodialysis (HF-HD), standardised dosing practices for tobramycin (or any aminoglycoside) are not established for the dialysis dependent patient

    Methods

    Following a 120mg intravenous dose of tobramycin 5 days prior, a 54 year old male with cystic fibrosis and end-stage renal disease recorded a plasma

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses